These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 31793630)
1. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. Matar M; Shamir R; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Ben-Horin S; Assa A Inflamm Bowel Dis; 2020 Oct; 26(11):1627-1635. PubMed ID: 31793630 [TBL] [Abstract][Full Text] [Related]
2. The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn's disease: a post hoc analysis. Hyams JS; Dubinsky M; Rosh J; Ruemmele FM; Eichner SF; Maa JF; Lazar A; Alperovich G; Mostafa NM; Robinson AM Aliment Pharmacol Ther; 2019 Jan; 49(2):155-164. PubMed ID: 30506693 [TBL] [Abstract][Full Text] [Related]
3. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring. Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979 [TBL] [Abstract][Full Text] [Related]
4. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Colombel JF; Jharap B; Sandborn WJ; Feagan B; Peyrin-Biroulet L; Eichner SF; Robinson AM; Mostafa NM; Zhou Q; Thakkar RB Aliment Pharmacol Ther; 2017 Jan; 45(1):50-62. PubMed ID: 27883215 [TBL] [Abstract][Full Text] [Related]
5. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Watanabe K; Matsumoto T; Hisamatsu T; Nakase H; Motoya S; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T; Clin Gastroenterol Hepatol; 2018 Apr; 16(4):542-549.e1. PubMed ID: 29104132 [TBL] [Abstract][Full Text] [Related]
6. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. Matsumoto T; Motoya S; Watanabe K; Hisamatsu T; Nakase H; Yoshimura N; Ishida T; Kato S; Nakagawa T; Esaki M; Nagahori M; Matsui T; Naito Y; Kanai T; Suzuki Y; Nojima M; Watanabe M; Hibi T; J Crohns Colitis; 2016 Nov; 10(11):1259-1266. PubMed ID: 27566367 [TBL] [Abstract][Full Text] [Related]
13. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. Nakase H; Matsumoto T; Watanabe K; Hisamatsu T J Gastroenterol; 2020 Sep; 55(9):824-832. PubMed ID: 32661927 [TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease. Faubion WA; Dubinsky M; Ruemmele FM; Escher J; Rosh J; Hyams JS; Eichner S; Li Y; Reilly N; Thakkar RB; Robinson AM; Lazar A Inflamm Bowel Dis; 2017 Mar; 23(3):453-460. PubMed ID: 28129288 [TBL] [Abstract][Full Text] [Related]
15. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial. Matar M; Shamir R; Lev-Zion R; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Assa A J Pediatr Gastroenterol Nutr; 2020 Aug; 71(2):237-242. PubMed ID: 32324651 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Sharma S; Eckert D; Hyams JS; Mensing S; Thakkar RB; Robinson AM; Rosh JR; Ruemmele FM; Awni WM Inflamm Bowel Dis; 2015 Apr; 21(4):783-92. PubMed ID: 25723614 [TBL] [Abstract][Full Text] [Related]
17. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2). Hisamatsu T; Kato S; Kunisaki R; Matsuura M; Nagahori M; Motoya S; Esaki M; Fukata N; Inoue S; Sugaya T; Sakuraba H; Hirai F; Watanabe K; Kanai T; Naganuma M; Nakase H; Suzuki Y; Watanabe M; Hibi T; Nojima M; Matsumoto T; J Gastroenterol; 2019 Oct; 54(10):860-870. PubMed ID: 31041545 [TBL] [Abstract][Full Text] [Related]
18. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study. Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG Inflamm Bowel Dis; 2024 Oct; 30(10):1714-1723. PubMed ID: 37951220 [TBL] [Abstract][Full Text] [Related]
19. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574 [TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience. Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]